Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 2/20 | 0.39 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.39 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30386379 | 1.00 | MAPK14 (0.43) | MAPK14CSNK1DGSK3BWNT3ARIPK3 | |
| SCHEMBL30387831 | 0.94 | MAPK14 (0.48) | MAPK14CSNK1DGSK3BWNT3ARIPK3 | |
| SCHEMBL25207160 | 0.94 | MAPK14 (0.48) | MAPK14CSNK1DGSK3BWNT3ARIPK3 | |
| SCHEMBL26735558 | 0.91 | MAPK14 (0.43) | MAPK14CSNK1DGSK3BWNT3ARIPK3 | |
| SCHEMBL30387494 | 0.90 | MAPK14 (0.45) | MAPK14CSNK1DGSK3BWNT3ARIOK2 | |
| SCHEMBL25206334 | 0.90 | MAPK14 (0.45) | MAPK14CSNK1DGSK3BWNT3ARIOK2 | |
| SCHEMBL25206069 | 0.87 | MAPK14 (0.46) | MAPK14CSNK1DGSK3BWNT3ARIOK2 | |
| SCHEMBL30387456 | 0.87 | MAPK14 (0.46) | MAPK14CSNK1DGSK3BWNT3ARIOK2 | |
| SCHEMBL25232727 | 0.86 | MAPK14 (0.43) | MAPK14CSNK1DGSK3BWNT3ARIPK3 | |
| SCHEMBL30387858 | 0.86 | MAPK14 (0.43) | MAPK14CSNK1DGSK3BWNT3ARIPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12565496-B2 | Substituted 1H-pyrrolo[3,2-b]pyridine compounds and methods of use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2026-03-03 | — | — | US | disclosed |
| EP-4188928-B1 | SUBSTITUTED 1 H-PYRROLO[3,2-B]PYRIDIN COMPOUNDS AND METHODS OF USE THEREOF | BAYER AG (DE) | 2024-07-24 | — | — | EP | disclosed |
| US-20230339939-A1 | SUBSTITUTED 1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-26 | — | — | US | disclosed |
| US-20230339939-A1 | SUBSTITUTED 1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-26 | — | — | US | disclosed |
| US-20230339939-A1 | SUBSTITUTED 1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-26 | — | — | US | disclosed |
| EP-4188928-A1 | SUBSTITUTED 1 H-PYRROLO[3,2-B]PYRIDIN COMPOUNDS AND METHODS OF USE THEREOF | Bayer Aktiengesellschaft (DE) | 2023-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12565496-B2 | Substituted 1H-pyrrolo[3,2-b]pyridine compounds and methods of use thereof | CYP1B1, CBR1, CYP4B1 | MAPK14 3698/4885CSNK1D 220/4885GSK3B 2089/4885 |
| US-20230339939-A1 | SUBSTITUTED 1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | CYP1B1, CYP4B1, CYP2C19 | MAPK14 2540/4885CSNK1D 501/4885GSK3B 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.